Last edition
News about "Novartis discontinues hydroxychloroquine trial for"
Novartis discontinues hydroxychloroquine trial for COVID-19 due to acute enrollment challenges
Novartis has made the decision to stop and discontinue its sponsored hydroxychloroquine(HCQ) clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible
Novartis Discontinues Hydroxychloroquine Trial For | 22/06/2020 | By Darshana | 232
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members